- Home
- IMCR vs PGNY Comparison
IMCR vs PGNY Comparison
Compare IMCR & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PGNY
- Stock Information
- Founded
- IMCR 2008
- PGNY 2008
- Country
- IMCR United Kingdom
- PGNY United States
- Employees
- IMCR N/A
- PGNY N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PGNY Misc Health and Biotechnology Services
- Sector
- IMCR Health Care
- PGNY Health Care
- Exchange
- IMCR Nasdaq
- PGNY Nasdaq
- Market Cap
- IMCR 1.8B
- PGNY 2.0B
- IPO Year
- IMCR 2021
- PGNY 2019
- Fundamental
- Price
- IMCR $37.20
- PGNY $22.55
- Analyst Decision
- IMCR Buy
- PGNY Buy
- Analyst Count
- IMCR 9
- PGNY 8
- Target Price
- IMCR $57.00
- PGNY $26.14
- AVG Volume (30 Days)
- IMCR 284.7K
- PGNY 1.0M
- Earning Date
- IMCR 11-05-2025
- PGNY 08-07-2025
- Dividend Yield
- IMCR N/A
- PGNY N/A
- EPS Growth
- IMCR N/A
- PGNY N/A
- EPS
- IMCR N/A
- PGNY 0.58
- Revenue
- IMCR $356,145,000.00
- PGNY $1,241,968,000.00
- Revenue This Year
- IMCR $31.83
- PGNY $9.92
- Revenue Next Year
- IMCR $8.50
- PGNY $9.82
- P/E Ratio
- IMCR N/A
- PGNY $40.36
- Revenue Growth
- IMCR 26.78
- PGNY 9.62
- 52 Week Low
- IMCR $23.15
- PGNY $13.39
- 52 Week High
- IMCR $39.33
- PGNY $26.76
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- PGNY 45.73
- Support Level
- IMCR $31.85
- PGNY $23.15
- Resistance Level
- IMCR $33.08
- PGNY $23.88
- Average True Range (ATR)
- IMCR 1.28
- PGNY 0.76
- MACD
- IMCR 0.50
- PGNY -0.02
- Stochastic Oscillator
- IMCR 100.00
- PGNY 15.15
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.